{
  "symbol": "JNJ",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2406,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.172
  },
  "top_positive": [
    {
      "sent": "Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;\u00a0and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties.",
      "score": 0.9961
    },
    {
      "sent": "Table of Contents Part I \u2014 Financial information Item 1 \u2014 Financial statements Johnson & Johnson and subsidiaries consolidated balance sheets (Unaudited; Dollars in Millions Except Share and Per Share Data) June 29, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 18,577 24,105 Marketable securities 303 417 Accounts receivable, trade, less allowances $ 185 (2024, $ 167 ) 17,846 14,842 Inventories (Note 2) 13,412 12,444 Prepaid expenses and other 4,360 4,085 Total current assets 54,498 55,893 Property, plant and equipment at cost 52,472 48,768 Less: accumulated depreciation ( 30,523 ) ( 28,250 ) Property, plant and equipment, net 21,949 20,518 Intangible assets, net (Note 3) 49,835 37,618 Goodwill (Note 3) 48,117 44,200 Deferred taxes on income (Note 5) 6,801 10,461 Other assets 12,189 11,414 Total assets $ 193,389 180,104 Liabilities and shareholders\u2019 equity Current liabilities: Loans and notes payable $ 11,526 5,983 Accounts payable 9,464 10,311 Accrued liabilities 7,404 8,549 Accrued rebates, returns and promotions 20,823 17,580 Accrued compensation and employee related obligations 3,298 4,126 Accrued taxes on income (Note 5) 1,665 3,772 Total current liabilities 54,180 50,321 Long-term debt (Note 4) 39,235 30,651 Deferred taxes on income (Note 5) 3,799 2,448 Employee related obligations (Note 6) 7,021 7,255 Long-term taxes payable (Note 5) 418 390 Other liabilities 10,263 17,549 Total liabilities $ 114,916 108,614 Commitments and Contingencies (Note 11) Shareholders\u2019 equity: Common stock \u2014 par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 14,305 ) ( 11,741 ) Retained earnings and Additional paid-in capital 165,371 155,791 Less: common stock held in treasury, at cost ( 713,064,000 and 712,921,000 shares) 75,713 75,680 Total shareholders\u2019 equity $ 78,473 71,490 Total liabilities and shareholders\u2019 equity $ 193,389 180,104 See Notes to Consolidated Financial Statements Form 10-Q 1 Table of Contents Johnson & Johnson and subsidiaries consolidated statements of earnings (Unaudited; Dollars & Shares in Millions Except Per Share Amounts) Fiscal Second Quarter Ended June 29, 2025 Percent to Sales June 30, 2024 Percent to Sales Sales to customers (Note 9) $ 23,743 100.0 % $ 22,447 100.0 % Cost of products sold 7,628 32.1 6,869 30.6 Gross profit 16,115 67.9 15,578 69.4 Selling, marketing and administrative expenses 5,889 24.8 5,681 25.3 Research and development expense 3,516 14.8 3,440 15.3 In-process research and development impairments \u2014 \u2014 194 0.9 Interest income ( 260 ) ( 1.1 ) ( 395 ) ( 1.8 ) Interest expense, net of portion capitalized 308 1.3 270 1.2 Other (income) expense, net 107 0.5 653 2.9 Restructuring (Note 12) 64 0.3 ( 13 ) 0.0 Earnings before provision for taxes on income 6,491 27.3 5,748 25.6 Provision for taxes on income (Note\u00a05) 954 4.0 1,062 4.7 Net earnings $ 5,537 23.3 % $ 4,686 20.9 % Net earnings per share (Note 8) Basic $ 2.30 $ 1.95 Diluted $ 2.29 $ 1.93 Avg.",
      "score": 0.9726
    },
    {
      "sent": "Percentages in chart are as a percent to total sales) Fiscal six months Q2 2025 versus Fiscal six months Q2 2024 Cost of products sold increased as a percent to sales driven by: \u2022 Increased intangible asset amortization expense related to the Intra-Cellular acquisition in the Innovative Medicine business \u2022 Unfavorable product mix driven by the decline of STELARA sales in the Innovative Medicine business \u2022 Unfavorable transactional currency in the Innovative Medicine business \u2022 Macroeconomic factors in the MedTech business The intangible asset amortization expense included in cost of products sold for the fiscal six months of 2025 and 2024 was $2.4\u00a0billion and $2.2\u00a0billion, respectively.",
      "score": 0.9612
    }
  ],
  "top_negative": [
    {
      "sent": "Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.",
      "score": -0.9531
    },
    {
      "sent": "Risks related to supply chain and operations \u2022 Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action; \u2022 Interruptions and breaches of the Company\u2019s information technology systems or those of the Company\u2019s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; \u2022 Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company\u2019s products; and \u2022 The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.",
      "score": -0.765
    },
    {
      "sent": "For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued.",
      "score": -0.765
    }
  ],
  "forward_snippets": [
    "This acquisition also includes a promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer\u2019s disease-related psychosis and agitation.",
    "The operational decline in Knees was driven by competitive pressures and market headwinds, partially offset by strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solutions."
  ],
  "curated_text": "Symbol: JNJ. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;\u00a0and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties. Table of Contents Part I \u2014 Financial information Item 1 \u2014 Financial statements Johnson & Johnson and subsidiaries consolidated balance sheets (Unaudited; Dollars in Millions Except Share and Per Share Data) June 29, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 18,577 24,105 Marketable securities 303 417 Accounts receivable, trade, less allowances $ 185 (2024, $ 167 ) 17,846 14,842 Inventories (Note 2) 13,412 12,444 Prepaid expenses and other 4,360 4,085 Total current assets 54,498 55,893 Property, plant and equipment at cost 52,472 48,768 Less: accumulated depreciation ( 30,523 ) ( 28,250 ) Property, plant and equipment, net 21,949 20,518 Intangible assets, net (Note 3) 49,835 37,618 Goodwill (Note 3) 48,117 44,200 Deferred taxes on income (Note 5) 6,801 10,461 Other assets 12,189 11,414 Total assets $ 193,389 180,104 Liabilities and shareholders\u2019 equity Current liabilities: Loans and notes payable $ 11,526 5,983 Accounts payable 9,464 10,311 Accrued liabilities 7,404 8,549 Accrued rebates, returns and promotions 20,823 17,580 Accrued compensation and employee related obligations 3,298 4,126 Accrued taxes on income (Note 5) 1,665 3,772 Total current liabilities 54,180 50,321 Long-term debt (Note 4) 39,235 30,651 Deferred taxes on income (Note 5) 3,799 2,448 Employee related obligations (Note 6) 7,021 7,255 Long-term taxes payable (Note 5) 418 390 Other liabilities 10,263 17,549 Total liabilities $ 114,916 108,614 Commitments and Contingencies (Note 11) Shareholders\u2019 equity: Common stock \u2014 par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 14,305 ) ( 11,741 ) Retained earnings and Additional paid-in capital 165,371 155,791 Less: common stock held in treasury, at cost ( 713,064,000 and 712,921,000 shares) 75,713 75,680 Total shareholders\u2019 equity $ 78,473 71,490 Total liabilities and shareholders\u2019 equity $ 193,389 180,104 See Notes to Consolidated Financial Statements Form 10-Q 1 Table of Contents Johnson & Johnson and subsidiaries consolidated statements of earnings (Unaudited; Dollars & Shares in Millions Except Per Share Amounts) Fiscal Second Quarter Ended June 29, 2025 Percent to Sales June 30, 2024 Percent to Sales Sales to customers (Note 9) $ 23,743 100.0 % $ 22,447 100.0 % Cost of products sold 7,628 32.1 6,869 30.6 Gross profit 16,115 67.9 15,578 69.4 Selling, marketing and administrative expenses 5,889 24.8 5,681 25.3 Research and development expense 3,516 14.8 3,440 15.3 In-process research and development impairments \u2014 \u2014 194 0.9 Interest income ( 260 ) ( 1.1 ) ( 395 ) ( 1.8 ) Interest expense, net of portion capitalized 308 1.3 270 1.2 Other (income) expense, net 107 0.5 653 2.9 Restructuring (Note 12) 64 0.3 ( 13 ) 0.0 Earnings before provision for taxes on income 6,491 27.3 5,748 25.6 Provision for taxes on income (Note\u00a05) 954 4.0 1,062 4.7 Net earnings $ 5,537 23.3 % $ 4,686 20.9 % Net earnings per share (Note 8) Basic $ 2.30 $ 1.95 Diluted $ 2.29 $ 1.93 Avg. Percentages in chart are as a percent to total sales) Fiscal six months Q2 2025 versus Fiscal six months Q2 2024 Cost of products sold increased as a percent to sales driven by: \u2022 Increased intangible asset amortization expense related to the Intra-Cellular acquisition in the Innovative Medicine business \u2022 Unfavorable product mix driven by the decline of STELARA sales in the Innovative Medicine business \u2022 Unfavorable transactional currency in the Innovative Medicine business \u2022 Macroeconomic factors in the MedTech business The intangible asset amortization expense included in cost of products sold for the fiscal six months of 2025 and 2024 was $2.4\u00a0billion and $2.2\u00a0billion, respectively. Top negative sentences: Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets. Risks related to supply chain and operations \u2022 Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action; \u2022 Interruptions and breaches of the Company\u2019s information technology systems or those of the Company\u2019s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; \u2022 Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company\u2019s products; and \u2022 The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Forward-looking snippets: This acquisition also includes a promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer\u2019s disease-related psychosis and agitation. The operational decline in Knees was driven by competitive pressures and market headwinds, partially offset by strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solutions."
}